Catalog No.
Product Name
Application
Product Information
Citations
-
Antifungal Agent
(E)-2-Octenal is an antifungal agent that disrupts cell membrane integrity and induces reactive oxygen species (ROS) accumulation. It effectively decreases the activity of phosphofructokinase and pyruvate kinase, inhibiting the growth of Neofusicoccum parvum by impairing mitochondrial energy metabolism. Additionally, (E)-2-Octenal demonstrates broad-spectrum efficacy against various fungi, including Sclerotium rolfsii, Metarhizium anisopliae sensu lato, and Aspergillus flavus, making it valuable for research on citrus blue mold and mango stem-end rot. -
Aphid Alarm Pheromone
(E)-β-Farnesene is an aphid alarm pheromone that functions primarily through its interaction with specific receptors, including a strong binding affinity for CDK2 with a score of -30.64 kcal/mol. This compound also demonstrates significant affinity for odorant-binding protein 3 (OBP3), making it valuable in studies of insect olfaction. Additionally, (E)-β-Farnesene serves as a feeding stimulant for the sand fly Lutzomyia longipalpis, facilitating research in insect behavior and ecology. -
Endogenous Metabolite
D-Gluconic acid is an endogenous metabolite that functions as a carboxylic acid, exhibiting notable antiseptic and chelating properties. This reagent is used in various biological research applications, including studies of metabolic pathways and chelation dynamics, and has potential utility in the development of therapeutic agents. Its role in cellular processes makes it a valuable tool for researchers investigating metabolic disorders and biochemical interactions. -
Endogenous Metabolite
Glucagon-Like Peptide (GLP) II, human is a 33-amino acid peptide derived from the C-terminal region of proglucagon, primarily synthesized by intestinal L cells. It plays a crucial role in promoting intestinal mucosal growth and inhibiting enterocyte apoptosis. This peptide is valuable in research focused on gastrointestinal health, metabolism, and potential therapeutic applications in intestinal disorders. -
PKM2 Inhibitor
PKM2 modulator 2 (compound C599) is a potent inhibitor of pyruvate kinase M2 (PKM2), a key regulator of cellular metabolism. This compound exhibits significant antiproliferative activity and induces apoptosis in various cancer cell lines. PKM2 modulator 2 is a valuable tool for research on glioblastoma and other malignancies where PKM2 plays a critical role in tumorigenesis. -
RARγ Inhibitor
ZSH-512 is a potent inhibitor of retinoic acid receptor gamma (RARγ). It demonstrates significant antiproliferative effects by inducing apoptosis in cancer cells, while concurrently downregulating key stemness markers such as CD133, NANOG, SOX2, and EPCAM. With its strong anticancer activity, ZSH-512 is a valuable tool for investigating therapeutic strategies in colorectal cancer research. -
HSP90 Inhibitor
17-Demethoxy-reblastatin is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting an IC50 value of 1.82 μM for yeast Hsp90 ATPase activity. This compound effectively inhibits the proliferation of cancer cell lines, including HepG2 and SMMC7721, while also reducing colony formation. Additionally, it induces apoptosis through mitochondrial and caspase-mediated pathways, making it a valuable reagent for cancer research and therapeutic investigations targeting Hsp90 activity. -
PDE5 Inhibitor
PDE5-IN-3 is a potent phosphodiesterase 5 (PDE5) inhibitor, exhibiting an IC50 of 1.57 nM. In addition to its primary mechanism, PDE5-IN-3 demonstrates moderate inhibition of epidermal growth factor receptor (EGFR) with an IC50 of 5.827 µM and significantly affects the Wnt/β-catenin signaling pathway with an IC50 of 1286.96 ng/mL. This compound has been shown to induce the intrinsic apoptotic mitochondrial pathway in HepG2 cells and displays strong antitumor activity, making it valuable for cancer research applications. -
Multi-targeted Antifolate
AGF347 is a potent multi-targeted antifolate that primarily inhibits serine hydroxymethyltransferase (SHMT)2 in mitochondria and SHMT1 in the cytosol, thereby disrupting de novo purine biosynthesis. This compound induces apoptosis, inhibits mTOR signaling, reduces glutathione (GSH) levels, and increases reactive oxygen species (ROS). AGF347 effectively inhibits the proliferation of both Cisplatin-sensitive and resistant epithelial ovarian cancer (EOC) cells and demonstrates significant antitumor efficacy in SKOV3 EOC xenograft mouse models, making it a valuable tool for ovarian cancer research. -
Ser/Thr Protease Inhibitor
ONO-3403 is an orally active serine/threonine protease inhibitor that targets key proteolytic processes. This compound has been shown to inhibit lipopolysaccharide (LPS)-induced production of tumor necrosis factor-alpha (TNF-α) and nitric oxide, demonstrating anti-inflammatory properties. Additionally, ONO-3403 exhibits cytotoxic effects by inhibiting cell growth and inducing apoptosis, making it a valuable tool in antitumor research. -
Hsp90/HDAC6 Inhibitor
HDAC6/HSP90-IN-2 is a dual inhibitor targeting both HDAC6 and Hsp90, exhibiting IC50 values of 105.7 nM and 61 nM, respectively. This compound demonstrates significant potential in cancer research, enabling the study of mechanisms involved in tumorigenesis and the development of novel therapeutic strategies. Its ability to modulate key cellular pathways associated with cancer progression makes it a valuable tool for investigating the role of HDAC6 and Hsp90 in various malignancies. -
Hsp90 Inhibitor
HSP90-IN-18 is a potent inhibitor of heat shock protein 90 (Hsp90), exhibiting an IC50 value of 0.39 μM. This compound effectively disrupts Hsp90 function, making it valuable for research into viral infections, neurodegenerative diseases, and inflammatory conditions. Its capability to modulate Hsp90 activity provides a useful tool for studying the biological pathways influenced by this essential chaperone protein. -
IDH1 Inhibitor
ZD-2767P is a reversible and competitive inhibitor of isocitrate dehydrogenase 1 (IDH1), with an IC50 value of 410 nM. This compound has been shown to effectively modulate IDH1 activity, making it a valuable tool for investigating metabolic pathways and oncogenic processes associated with IDH1 mutations. ZD-2767P is suitable for research applications focused on cancer biology and metabolic regulation. -
PDE5/HDAC Inhibitor
PDE5/HDAC-IN-1 is a dual inhibitor of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) with IC50 values of 46.3 nM and 14.5 nM, respectively. This compound has demonstrated the capability to induce cell apoptosis and exhibits significant anticancer activities. PDE5/HDAC-IN-1 is a valuable tool for research in cancer therapeutics and epigenetic modulation. -
Mutant IDH1/NAMPT Inhibitor
Mutant IDH1/NAMPT-IN-1 is a dual inhibitor targeting mutant isocitrate dehydrogenase 1 (mutant IDH1) and nicotinamide phosphoribosyltransferase (NAMPT), with IC50 values of 14.93 nM and 12.56 nM, respectively. This compound effectively induces apoptosis, making it a valuable tool for research into cancer mechanisms and treatment strategies. Additionally, Mutant IDH1/NAMPT-IN-1 demonstrates the capability to cross the blood-brain barrier, enhancing its potential for applications in neurological studies and therapies. -
PDEIII Inhibitor
Anagrelide hydrochloride monohydrate is a selective inhibitor of phosphodiesterase type III (PDE3), with an IC50 value of 36 nM. This imidazoquinazoline derivative effectively inhibits platelet aggregation and reduces bone marrow megakaryocytopoiesis. Additionally, Anagrelide hydrochloride monohydrate demonstrates the capability to decrease cell proliferation and induce apoptosis in gastrointestinal stromal tumor (GIST) cells in vitro, making it relevant for research in hematology and oncology. Its platelet-lowering properties contribute to its antithrombopoietic effects. -
NAMPT Inhibitor
Nampt-IN-16 is a potent NAMPT inhibitor exhibiting an IC50 value of 0.15 μM. This compound effectively reduces intracellular levels of NAD+ and ATP, leading to the inhibition of proliferation, migration, and invasion in gastric cancer cells. Additionally, Nampt-IN-16 induces cell cycle arrest and apoptosis while altering cellular metabolism. It is a valuable tool for research focused on tumors, particularly gastric cancer. -
TrxR Inhibitor
TrxR Inhibitor D9 is a potent and selective inhibitor of thioredoxin reductase (TrxR) with an EC50 of 2.8 nM. This compound effectively inhibits tumor proliferation in both in vitro and in vivo studies, making it a valuable tool for cancer research. Its ability to modulate TrxR activity supports investigations into redox biology and therapeutic strategies targeting oxidative stress in cancer cells. -
PDE4 Inhibitor
GPD-1116 is a potent inhibitor of Phosphodiesterase (PDE) 4 and PDE1, demonstrating oral bioactivity. This compound effectively reduces smoke-induced apoptosis in lung cells, making it relevant for respiratory research. GPD-1116 shows promise in various animal disease models, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma, and pulmonary hypertension, supporting its potential therapeutic applications in pulmonary disorders. -
MGF Derivative
MGF24 is a protease-resistant derivative of mechanical growth factor (MGF) that primarily targets the neuroprotective pathway. It protects dopaminergic neurons from 6-Hydroxydopamine (6-OHDA)-induced apoptosis by inducing the expression of Heme oxygenase-1 (HO-1). MGF24 activates Protein Kinase C epsilon (PKC-ε) to stimulate Nrf2 activity, leading to enhanced HO-1 levels. This compound demonstrates significant neuroprotective effects and has potential applications in research related to neurological disorders such as stroke, nerve injury, and amyotrophic lateral sclerosis, as well as providing cardioprotective benefits in myocardial ischemia models. -
Hsp90-Cdc37 PPI Inhibitor
Hsp90-Cdc37-IN-4 is a selective inhibitor of the Hsp90-Cdc37 protein-protein interaction (PPI). This compound disrupts the interaction by inhibiting casein kinase 2 (CK2), leading to reduced phosphorylation of Cdc37 at Serine 13. In cellular assays, Hsp90-Cdc37-IN-4 has been shown to induce G0/G1 cell cycle arrest and activate apoptotic pathways via the mitochondria. Additionally, it exhibits significant anti-breast cancer properties, making it a valuable tool in cancer research. -
IDO/Tubulin Inhibitor
HI5 is a potent inhibitor of indoleamine 2,3-dioxygenase (IDO) and tubulin, demonstrating an IC50 of 70 nM in HeLa cells. It effectively reduces kynurenine production, thereby promoting T cell activation and proliferation. Additionally, HI5 interferes with tubulin polymerization and migration, induces G2/M phase cell cycle arrest, and triggers apoptosis through a mitochondrial-dependent pathway, leading to increased reactive oxidative stress. HI5 is suitable for research in anticancer applications. -
HSP90 Inhibitor
HSP90-IN-13 is a potent inhibitor of Heat Shock Protein 90 (HSP90) with an IC50 of 25.07 nM. This compound exhibits multi-target activity, affecting key proteins such as Epidermal Growth Factor Receptor (EGFR), Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), and Topoisomerase-2. HSP90-IN-13 promotes cell cycle arrest at the G2/M phase and induces apoptosis in MCF-7 cancer cells via a mitochondrial-mediated pathway, making it a valuable reagent for cancer research and therapeutic studies. -
MAO-B/Acetylcholinesterase Inhibitor
MAO-B-IN-26 is a selective inhibitor of monoamine oxidase B (MAO-B) and acetylcholinesterase, demonstrating neuroprotective properties against β-amyloid (Aβ) induced cytotoxicity in SH-SY5Y cells. This compound effectively mitigates morphological alterations, reactive oxygen species (ROS) generation, and membrane damage associated with neurodegeneration. Additionally, MAO-B-IN-26 suppresses Aβ-induced autophagy and apoptosis, making it a valuable tool for research focused on therapeutic strategies for Alzheimer's disease. -
TrxR Inhibitor
TrxR-IN-6 is an inhibitor of thioredoxin reductase (TrxR), a key enzyme in maintaining the cellular redox balance. This compound induces the accumulation of reactive oxygen species (ROS), leading to mitochondrial dysfunction, endoplasmic reticulum (ER) stress, and DNA damage. TrxR-IN-6 effectively promotes oxidative stress, resulting in apoptosis, making it a valuable tool for cancer research and studies focusing on oxidative stress mechanisms. -
PARP1/NAMPT Inhibitor
PARP1/NAMPT-IN-1 is a potent dual inhibitor of PARP1 and NAMPT, exhibiting IC50 values of 1.2 nM and 6.7 nM, respectively. This compound disrupts the homologous recombination repair pathway, leading to the accumulation of DNA double-strand breaks, which induces cell cycle arrest and apoptosis. Additionally, PARP1/NAMPT-IN-1 demonstrates antimigratory effects and has shown significant antitumor activity in a breast cancer xenograft model. It is a valuable tool for research on triple-negative breast cancer (TNBC). -
Endogenous Metabolite
Desmosterol is a cholesterol precursor involved in the Bloch pathway of cholesterol biosynthesis. As an endogenous metabolite, it plays a critical role in the study of cholesterol metabolism. Desmosterol functions as a liver X receptor (LXR) activator and SREBP inhibitor, which can mitigate macrophage inflammasome activation, thereby reducing vascular inflammation and the risk of atherosclerosis. Furthermore, lower levels of Desmosterol can lead to increased production of mitochondrial reactive oxygen species (ROS) in macrophages and activate the NLRP3 inflammasome through pyrin domain mechanisms. This compound is valuable for research focused on inflammation, metabolic processes, and cardiovascular diseases. -
Anti-inflammatory Agent
NLRP3-IN-72 is a benzimidazole derivative that functions as an anti-inflammatory agent by specifically targeting the NLRP3 inflammasome. It demonstrates significant biological activity with an IC50 of 0.3 μM for inhibiting NLRP3-mediated IL-1β secretion, a PD50 of 0.4 μM for protecting against pyroptosis, and an EC50 of 0.6 μM for the induction of heme oxygenase-1 (HO-1). These properties make NLRP3-IN-72 a valuable tool for research into inflammatory processes and potential therapeutic interventions. -
PD-L1/NAMPT Inhibitor
PD-L1/Nampt-IN-1 is a dual inhibitor targeting PD-L1 and NAMPT (nicotinamide phosphoribosyltransferase) with IC50 values of 63 nM and 582 nM, respectively. This compound exhibits cross-species affinity with comparable KD values for human PD-L1 (52.6 nM) and mouse PD-L1 (49.1 nM). PD-L1/Nampt-IN-1 facilitates tumor growth inhibition by enhancing the tumor immune microenvironment, making it a valuable tool for research in melanoma studies. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-4 is a potent dual-target inhibitor of CYP51 and PD-L1, demonstrating IC50 values of 0.17 μM and 0.021 μM, respectively. This compound exhibits significant antifungal activity and is effective against drug-resistant fungal strains in vitro. CYP51/PD-L1-IN-4 is suitable for research applications focused on fungal infections and the interplay between fungal pathogens and immune checkpoint regulation. -
Anti-Inflammatory Agent; LXRα Activator
Taraxasterol is a pentacyclic triterpenoid that acts as an LXRα activator, demonstrating significant anti-inflammatory properties. Isolated from Taraxacum mongolicum, this compound has potential applications in the study of immune-inflammatory diseases, contributing to our understanding of metabolic regulation and inflammatory pathways. Researchers exploring therapeutic strategies for inflammatory conditions may find Taraxasterol an invaluable tool for investigation. -
Drug Metabolite
3-O-Methyldopa is a metabolite of L-DOPA that can effectively cross the blood-brain barrier. This compound has been shown to inhibit the astrocyte-mediated protective effects of L-DOPA on dopaminergic neurons, offering insights into its role in neurobiology. Additionally, 3-O-Methyldopa exhibits antidepressant and neuroprotective properties, making it a valuable tool for research into nervous system disorders, including depression and Parkinson's disease. -
HIFU Enhancer
Perfluorohexane functions as a HIFU (high-intensity focused ultrasound) enhancer, improving the efficacy and precision of ultrasound therapies while minimizing collateral damage to surrounding tissues. This perfluorocarbon compound has been shown to elevate the levels of heme oxygenase-1 (HO-1) and interleukin-10 (IL-10), thereby exhibiting antioxidant properties. Additionally, perfluorohexane plays a significant role in mitigating lung injury induced by lipopolysaccharide (LPS), making it a valuable tool for research into acute lung injury and related therapeutic applications. -
Endogenous Metabolite
5-Methoxy-DL-tryptophan is an endogenous metabolite that exhibits anti-inflammatory properties. This compound is known to inhibit lipopolysaccharide-induced release of interleukin-6 (IL-6), thereby suggesting its role in inflammatory processes. Its biological activity makes it a valuable tool for research in the context of atherosclerosis and related inflammatory conditions. -
PDE2/CDK2 Inhibitor
Aristolochic acid D is a selective inhibitor of PDE2 with an IC50 of 4.673 μM and CDK2 with an IC50 of 25 μM, derived from Aristolochia indica L. This compound demonstrates significant anti-inflammatory properties while exhibiting a non-carcinogenic and non-nephrotoxic profile. Aristolochic acid D is valuable for research applications focused on inflammation and tumor-related diseases, offering insights into therapeutic strategies. -
PDE4 Inhibitor
Morcamilast is a selective and orally active phosphodiesterase 4 (PDE4) inhibitor, exhibiting IC50 values of 1.28 nM for PDE4A1A, 2.33 nM for PDE4B1, and 1.63 nM for PDE4D2. This compound demonstrates significant anti-inflammatory activity by inhibiting the lipopolysaccharide (LPS)-induced release of pro-inflammatory cytokines, including TNF-α, IL-12/23p40, IL-23, and IL-17A in human peripheral blood mononuclear cells (PBMCs) and T cells. Morcamilast also exhibits antipruritic effects, making it a valuable tool for investigating psoriasis, atopic dermatitis, and various other inflammatory disorders. -
PDE1C Inhibitor
PDE1-IN-9 is a selective inhibitor of phosphodiesterase 1 (PDE1), demonstrating an IC50 of 11 nM for PDE1C. This compound significantly reduces the mRNA expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, as well as iNOS, while inhibiting the production of nitric oxide (NO) and reactive oxygen species (ROS). PDE1-IN-9 also showcases favorable metabolic stability in rat liver microsomes, making it a valuable tool for studying PDE1-related pathways and inflammatory responses. -
PDE4 Inhibitor
Mesopram is a selective phosphodiesterase (PDE) 4 inhibitor that effectively reduces the synthesis of pro-inflammatory cytokines, including TNF-α and IFN-γ. This compound has shown efficacy in alleviating Dextran sulfate sodium (DSS)-induced colitis in murine models, making it a valuable tool for research in chronic inflammatory diseases. Mesopram can be employed to investigate therapeutic strategies aimed at modulating inflammatory responses. -
PPARγ Modulator
GED 0507-34-Levo is an orally active modulator of PPARγ. This compound effectively downregulates the expression of TGF-β, Smad3, IL-13, and CTGF in colon tissue. GED 0507-34-Levo has demonstrated therapeutic potential in improving symptoms of DSS-induced chronic colitis and associated fibrosis, making it a valuable tool for research in inflammatory bowel diseases and fibrotic disorders. -
AhR Modulator
AhR Modulator-1 (6-MCDF) is a selective and orally active modulator of the aryl hydrocarbon receptor (AhR). This compound demonstrates significant inhibition of metastasis by reducing vascular endothelial growth factor (VEGF) production in prostatic tissues prior to tumor formation. Additionally, AhR Modulator-1 exhibits anti-estrogenic effects in the rat uterus, making it a valuable tool for investigating the roles of AhR in cancer biology and endocrine regulation. -
Drug Metabolite
Regorafénib N-oxyde (M2) is an active metabolite of Regorafenib, functioning as a multi-target inhibitor. It effectively targets VEGFR1/2/3, PDGFRβ, Kit, RET, and Raf-1, exhibiting IC50 values of 13, 4.2, 46, 22, 7, 1.5, and 2.5 nM, respectively. This compound is essential for studies involving cancer research and drug metabolism, providing insights into the pharmacological effects and therapeutic potential of Regorafenib. -
MAO-A/DYRK1A Inhibitor
Norharmine is a Harmine analogue that functions as an inhibitor of monoamine oxidase A (MAO-A) and dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A). It exhibits weak inhibitory activity against MAO-A and demonstrates certain inhibitory effects on DYRK1A, positioning it as a valuable tool for research in neurobiology and cellular signaling pathways. Norharmine is useful in studies focusing on mood disorders and cognitive functions related to these kinase targets. -
Endogenous Metabolite
Ethyl glucuronide is an endogenous metabolite of ethanol, serving as a reliable biomarker for alcohol exposure. It accumulates in hair, providing a measure of alcohol intake over extended periods. Additionally, ethyl glucuronide acts as an agonist for Toll-like receptor 4 (TLR4), making it relevant in studies of inflammatory responses and alcohol metabolism. -
Histamine H1 Receptor Antagonist/5-Lipoxygenase Inhibitor
UCB-35440 is an orally active antagonist of the histamine H1 receptor and a selective inhibitor of 5-lipoxygenase. It demonstrates significant inhibition of leukotriene B4 (LTB4) formation in human whole blood, as well as a reduction in polymorphonuclear cell infiltration in mouse models. UCB-35440 also effectively inhibits histamine-induced bronchoconstriction and alleviates skin inflammation in guinea pig studies. This compound is suitable for research applications related to asthma and inflammatory skin conditions. -
PDE3/PDE4/PDE5/HRH1 Inhibitor
Fenspiride is a potent inhibitor of phosphodiesterase 3 (PDE3), phosphodiesterase 4 (PDE4), and phosphodiesterase 5 (PDE5), with -log IC50 values of 3.44, 4.16, and approximately 3.8, respectively. Additionally, it acts as an antagonist of the H1-histamine receptor, contributing to its anti-inflammatory properties. Fenspiride is primarily utilized in research related to respiratory diseases, offering insights into mechanisms of action and potential therapeutic applications. -
5-Lipoxygenase Inhibitor
Linetastine is a potent, orally active inhibitor of 5-Lipoxygenase, an enzyme critical in the synthesis of leukotrienes. By inhibiting this pathway, Linetastine demonstrates significant antihistamine activity, effectively reducing leukotriene B4 and C4 release from calcium ionophore-stimulated human leukocytes. This compound is particularly useful in research applications focused on inflammatory processes and allergic responses, providing insights into the modulation of leukotriene-mediated pathways. -
HSP70 Ligand
HSP70 Ligand 1 serves as a ligand for the heat shock protein 70 (HSP70), facilitating the development of PROTAC molecules. This compound is instrumental in synthesizing PROTAC HSP70 Degrader-1, enabling targeted protein degradation studies. It is valuable for researchers investigating HSP70's role in cellular stress responses and therapeutic applications. -
Endogenous Metabolite
Palmitic acid sodium is a long-chain saturated fatty acid that serves as an endogenous metabolite. It has been shown to induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in mouse granulosa cells. This compound is commonly utilized to establish a cell steatosis model, making it valuable for research into metabolic disorders and related cellular mechanisms. -
Combined with Hsp90
AMP-PCP disodium is an ATP analogue that specifically targets the N-terminal domain of Hsp90, exhibiting a dissociation constant (Kd) of 3.8 μM. By binding to Hsp90, AMP-PCP disodium promotes the formation of its active homodimer, facilitating studies on protein folding and maturation. This reagent is valuable for research applications focusing on molecular chaperones and their roles in cellular stress responses. -
HSP Inhibitor
Apatorsen sodium is a 2'-methoxyethyl-modified antisense oligonucleotide targeting Hsp27. It effectively reduces Hsp27 mRNA and protein levels, disrupting stress-induced cytoprotective functions, promoting apoptosis, inhibiting tumor growth, and preventing metastasis. This compound is relevant for research applications in non-small cell lung cancer, castration-resistant prostate cancer, breast cancer, ovarian cancer, and bladder cancer.
